Tumors of the Central Nervous System, Volume 2
Kurzinformation
inkl. MwSt. Versandinformationen
Artikel zZt. nicht lieferbar
Artikel zZt. nicht lieferbar

Beschreibung
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained. von Hayat, M. A.
Produktdetails
So garantieren wir Dir zu jeder Zeit Premiumqualität.
Über den Autor
- hardcover
- 760 Seiten
- Erschienen 2024
- Academic Press
- paperback
- 523 Seiten
- Erschienen 2015
- American Registry of Pathology
- hardcover
- 236 Seiten
- Erschienen 2003
- Springer
- hardcover
- 128 Seiten
- Erschienen 2014
- Thieme Medical Publishers
- hardcover
- 359 Seiten
- Erschienen 2016
- Springer
- Gebunden
- 1336 Seiten
- Erschienen 2004
- Springer
- hardcover
- 276 Seiten
- Erschienen 2021
- American Registry of Pathology
- Kartoniert
- 300 Seiten
- Erschienen 2016
- Urban & Fischer Verlag/Else...
- paperback
- 400 Seiten
- Erschienen 2004
- Springer
- hardcover
- 576 Seiten
- Erschienen 2010
- Wiley-Blackwell
- hardcover
- 1006 Seiten
- Erschienen 2024
- Academic Press
- paperback
- 320 Seiten
- Erschienen 2002
- Richard Pflaum Verlag




